Interested in bioinformatics and looking for a new challenge? We are looking for exceptional and highly motivated people who want to make a difference.
Check out our Careers Section
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D.
The discovery, development and characterization of biopharmaceuticals generates huge volumes of complex data that needs to be captured, organized, integrated, processed and analyzed. The Genedata Biopharma Platform, developed in close collaboration with leading biopharma R&D organizations, has been adopted by a rapidly growing number of globally leading biopharmaceutical companies to streamline their biopharma R&D.
In the era of precision medicine clinical trials have become highly targeted and biomarker-based. The increased use of omic technologies, in particular next generation sequencing (NGS), poses significant challenges to R&D organizations, who must generate timely results from the huge volumes of data, and at the same time, ensure full regulatory compliance. Genedata Profiler™ translates omics data into meaningful scientific insights for precision medicines while addressing regulatory requirements.
SCIEX announces its participation in Genedata's Ready-to-Run Partner Program, covering the full suite of products in the Genedata Biopharma Platform.
Genedata shares insights with Bio-IT World on industry drivers for the development of Genedata Imagence.
Genedata talks with Biocompare about the impact of AI-based solutions—such as Genedata Imagence®—on drug discovery.
Deep learning is increasingly being used for a wide range of applications, from speech recognition to self-driving cars. Several recent publications have shown how this technology can be applied for high-content screening image analysis, but no comprehensive workflow from training data creation to pharmaceutical productive use has existed. Until now.